The benefits associated with medical cannabis therapy may be overestimated because of inadequate blinding in clinical trials. Many trials are flawed by inadequate blinding because subjects can distinguish between active cannabis and placebo. It is difficult to design a well-blinded study for cannabis therapy; in the meantime we should use caution when interpreting the findings of cannabis trials. (Psychiatry Advisor)